<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00451048</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00211</org_study_id>
    <secondary_id>PHL-063</secondary_id>
    <secondary_id>CDR0000535656</secondary_id>
    <secondary_id>N01CM62203</secondary_id>
    <nct_id>NCT00451048</nct_id>
  </id_info>
  <brief_title>Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia</brief_title>
  <official_title>A Phase II Study of Sunitinib Malate (SutentÂ®; SU11248) in Patients With Intermediate-2 or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well sunitinib works in treating patients with&#xD;
      myelodysplastic syndromes or chronic myelomonocytic leukemia. Sunitinib may stop the growth&#xD;
      of abnormal cells by blocking some of the enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the overall response rate (complete response, partial response, or hematological&#xD;
      improvement) in patients with intermediate-2 or high-risk myelodysplastic syndromes or&#xD;
      chronic myelomonocytic leukemia treated with sunitinib malate.&#xD;
&#xD;
      II. Determine the duration of response in patients treated with this drug. III. Determine the&#xD;
      overall survival of patients treated with this drug. IV. Determine the progression-free&#xD;
      survival of patients treated with this drug. V. Determine the time to disease progression in&#xD;
      patients treated with this drug.&#xD;
&#xD;
      VI. Determine the toxicity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 4 weeks&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 3-4 weeks and then monthly&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (Complete Response, Partial Response, or Hematologic Improvement) Defined by the International Working Group Criteria</measure>
    <time_frame>Up to 6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number Participants With Complete, Partial or Hematologic Improvement Response</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Assessed by achievement of Complete Response (CR), Partial Response (PR) or Hematologic Improvement (HI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>At 6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>At 6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>At 6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest Severity of Observed Adverse Events Assessed by Common Terminology Criteria or Adverse Events Version 3.0 (CTCAE v3.0)</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>de Novo Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Secondary Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive sunitinib malate (SU11248) by mouth once a day. Treatment may continue for as long as benefit is shown.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>SU11248</other_name>
    <other_name>sunitinib</other_name>
    <other_name>Sutent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  MDS syndromes meeting 1 of the following: Intermediate-2 disease, high-risk disease&#xD;
             (IPSS score&gt;=1.5)&#xD;
&#xD;
          -  CMML: WBC&gt;12,000/mm^3, Intermediate-2 disease with WBC=&lt;12,000/mm^3, high-risk disease&#xD;
             (IPSS score&gt;=1.5) with WBC=&lt;12,000/mm^3&#xD;
&#xD;
          -  Patients with insufficient/inadequate metaphases for cytogenetic analysis are eligible&#xD;
             if bone marrow blasts are &gt;10% and/or 2-3 cytopenias are present&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Life expectancy&gt;12 weeks&#xD;
&#xD;
          -  ECOG PS 0-2/Karnofsky PS 60-100%&#xD;
&#xD;
          -  Calcium=&lt;3.0 mmol/L&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT=&lt;2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal/creatinine clearance&gt;=60 mL/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No history of significant ECG abnormalities including but not limited to: ventricular&#xD;
             arrhythmias (ventricular tachycardia, ventricular fibrillation&gt;=3 beats in a row); QTc&#xD;
             prolongation (i.e.QTc interval&gt;=500msec)&#xD;
&#xD;
          -  No history of allergic reaction to compounds of similar chemical/biological&#xD;
             composition to sunitinib malate&#xD;
&#xD;
          -  No NYHA class III-IV congestive heart failure&#xD;
&#xD;
          -  Patients with history of NYHA class II congestive heart failure who are asymptomatic&#xD;
             on treatment are eligible&#xD;
&#xD;
          -  No abdominal fistula/G perforation/intraabdominal abscess within past 28 days&#xD;
&#xD;
          -  No serious cardiovascular disease within past 12 months including: cerebrovascular&#xD;
             accident or transient ischemic attack, myocardial infarction, cardiac arrhythmia,&#xD;
             stable or unstable angina, symptomatic congestive heart failure, coronary or&#xD;
             peripheral artery bypass graft or stenting&#xD;
&#xD;
          -  No pulmonary embolism within past 12 months&#xD;
&#xD;
          -  No uncontrolled hypertension (systolic BP&gt;=140 mmHg/diastolic BP&gt;=90 mmHg)&#xD;
&#xD;
          -  No condition impairing ability to swallow/retain sunitinib malate tablets including:&#xD;
             GI tract disease resulting in inability to take oral medication, requirement for IV&#xD;
             alimentation, prior surgical procedures affecting absorption, active peptic ulcer&#xD;
             disease&#xD;
&#xD;
          -  No serious/nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No uncontrolled pre-existing thyroid abnormality&#xD;
&#xD;
          -  No concurrent uncontrolled illness including ongoing/active infection&#xD;
&#xD;
          -  No psychiatric illness/social situation that would preclude study participation&#xD;
&#xD;
          -  Not pregnant/nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  4 weeks since prior major surgery&#xD;
&#xD;
          -  Prior central thoracic radiotherapy that included heart in radiotherapy port allowed&#xD;
             provided NYHA congestive heart failure=&lt;class II&#xD;
&#xD;
          -  Prior anthracycline exposure allowed provided NYHA congestive heart failure=&lt;class II&#xD;
&#xD;
          -  No other prior therapy for MDS/CMML except epoetin alfa, darbepoetin alfa, filgrastim&#xD;
             or sargramostim&#xD;
&#xD;
          -  At least 2 weeks since prior epoetin alfa&#xD;
&#xD;
          -  At least 4 weeks since prior darbepoetin alfa&#xD;
&#xD;
          -  No other prior antiangiogenic agents including but not limited to: bevacizumab,&#xD;
             sorafenib tosylate, pazopanib hydrochloride, AZD2171, vatalanib, VEGF Trap&#xD;
&#xD;
          -  More than 7 days since prior and no concurrent potent CYP3A4 inhibitors&#xD;
&#xD;
          -  More than 12 days since prior and no concurrent potent CYP3A4 inducers including:&#xD;
             Rifampin, Rifabutin, Carbamazepine, Phenobarbital, Phenytoin, Hypericum perforatum,&#xD;
             Efavirenz, Tipranavir&#xD;
&#xD;
          -  No concurrent birth control patch/oral birth control pills/depot/injectable birth&#xD;
             control methods&#xD;
&#xD;
          -  No concurrent therapeutic coumarin-derivative anticoagulants&#xD;
&#xD;
          -  Low dose(=&lt;2mg) warfarin for prophylaxis of thrombosis allowed&#xD;
&#xD;
          -  Low molecular weight heparin allowed if INR=&lt;1.5&#xD;
&#xD;
          -  No concurrent agents with proarrhythmic potential including: Terfenadine, Quinidine,&#xD;
             Procainamide, Disopyramide, Sotalol, Probucol, Bepridil, Haloperidol, Risperidone,&#xD;
             Indapamide, Flecainide acetate&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Yee</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network-Princess Margaret Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre- Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 20, 2007</study_first_submitted>
  <study_first_submitted_qc>March 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2007</study_first_posted>
  <results_first_submitted>August 20, 2014</results_first_submitted>
  <results_first_submitted_qc>August 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 1, 2014</results_first_posted>
  <last_update_submitted>July 27, 2018</last_update_submitted>
  <last_update_submitted_qc>July 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I</title>
          <description>Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown.&#xD;
sunitinib malate: Given orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown.&#xD;
sunitinib malate: Given orally</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="62" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate (Complete Response, Partial Response, or Hematologic Improvement) Defined by the International Working Group Criteria</title>
        <time_frame>Up to 6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown.&#xD;
sunitinib malate: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (Complete Response, Partial Response, or Hematologic Improvement) Defined by the International Working Group Criteria</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Participants With Complete, Partial or Hematologic Improvement Response</title>
        <description>Assessed by achievement of Complete Response (CR), Partial Response (PR) or Hematologic Improvement (HI)</description>
        <time_frame>Up to 6 years</time_frame>
        <population>No patient achieved CR, PR or HI as response.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown.&#xD;
sunitinib malate: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Number Participants With Complete, Partial or Hematologic Improvement Response</title>
          <description>Assessed by achievement of Complete Response (CR), Partial Response (PR) or Hematologic Improvement (HI)</description>
          <population>No patient achieved CR, PR or HI as response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>At 6 months and 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown.&#xD;
sunitinib malate: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" lower_limit="9.7" upper_limit="NA">95% confidence - 9.7 months to not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>At 6 months and 1 year</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown.&#xD;
sunitinib malate: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <time_frame>At 6 months and 1 year</time_frame>
        <population>Date were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown.&#xD;
sunitinib malate: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <population>Date were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Highest Severity of Observed Adverse Events Assessed by Common Terminology Criteria or Adverse Events Version 3.0 (CTCAE v3.0)</title>
        <time_frame>Up to 6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown.&#xD;
sunitinib malate: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Highest Severity of Observed Adverse Events Assessed by Common Terminology Criteria or Adverse Events Version 3.0 (CTCAE v3.0)</title>
          <units>highest grade of adverse event reported</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown.&#xD;
sunitinib malate: Given orally</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Anal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Encephalitis infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Karen Yee</name_or_title>
      <organization>Princess Margaret Hospital</organization>
      <phone>416-946-4495</phone>
      <email>karen.yee2@uhn.on.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

